Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2104 | Lactoferrin (Apolactoferrin) Wiki | 1.00 |
| drug316 | Antibody Test Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients. The study was approved by the ethical committee of the Egyptian Center for Research and Regenerative Medicine in 11-5-2020.
Description: Comparing the influence of the intervention on the Survival rate.
Measure: Survival rate. Time: up to 8 weeks.Description: For mild/moderate symptoms patients: fever, cough and other symptoms relieved with improved lung CT - For severe symptoms patients: fever, cough and other symptoms relieved with improved lung CT, and oxygen saturation by pulse oximetry (SPO2 )> 93% for nonasthmatic patients, and from 88-92% in asthmatic patients.
Measure: Rate of disease remission. Time: up to 4 weeks.Description: Comparing the influence of the intervention on the PCR negative results.
Measure: The number of patients with PCR negative results. Time: up to 4 weeks.Description: Recording the changes from severe to moderate or mild and the time taken.
Measure: Mean change in the disease severity (clinical assessment). Time: up to 4 weeks.Description: Recording the changes in blood pressure mmHg.
Measure: Mean change in blood pressure. Time: up to 4 weeks.Description: Recording the changes in heart rate in beat/second.
Measure: Mean change in heart beats. Time: up to 4 weeks.Description: Recording the changes in body temperature in Celsius.
Measure: Mean change in body temperature. Time: up to 4 weeks.Description: Recording the changes in the respiratory rate in breath/minute.
Measure: Mean change in body respiratory rate. Time: up to 4 weeks.Description: Recording the changes in arterial oxygen saturation in mmHg.
Measure: Mean change in oxygen saturation. Time: up to 4 weeks.Description: Recording the changes in the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PF ratio).
Measure: Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (PF ratio). Time: up to 4 weeks.Description: Recording the changes in complete blood picture (CBC) in cells per liter.
Measure: Mean change in complete blood picture (CBC). Time: up to 4 weeks.Description: Recording the changes in C reactive protein (CRP) in mg/L.
Measure: Mean change in C reactive protein (CRP). Time: up to 4 weeks.Description: Recording the changes in erythrocyte sedimentation rate (ESR) in mm/hr.
Measure: Mean change in erythrocyte sedimentation rate (ESR). Time: up to 4 weeks.Description: Recording the changes in D-dimer in ng/mL.
Measure: Mean change in D-dimer. Time: up to 4 weeks.Description: Recording the changes in ferritin in ng/mL.
Measure: Mean change in ferritin. Time: up to 4 weeks.Description: Recording the changes in liver Albumin in g/L.
Measure: Mean change in liver Albumin. Time: up to 4 weeks.Description: Recording the changes in total and direct Bilirubin in mg/dL.
Measure: Mean change in total and direct Bilirubin. Time: up to 4 weeks.Description: Recording the changes in prothrombin time (PT), partial thromboplastin time (PTT ) in seconds and calculating International Normalized Ratio (INR).
Measure: Mean change in prothrombin time (PT) and partial thromboplastin time (PTT ). Time: up to 4 weeks.Description: Recording the changes in aspartate aminotransferase (AST) in IU/L.
Measure: Mean change in aspartate aminotransferase (AST). Time: up to 4 weeks.Description: Recording the changes in Alanine Aminotransferase (ALT) in IU/L.
Measure: Mean change in Alanine Aminotransferase (ALT). Time: up to 4 weeks.Description: Recording the changes in Blood Urea Nitrogen (BUN) in mg/dL.
Measure: Mean change in Blood Urea Nitrogen (BUN). Time: up to 4 weeks.Description: Recording the changes in Serum Creatinine in mg/dL.
Measure: Mean change in Serum Creatinine. Time: up to 4 weeks.Description: Recording the changes in Serum Creatinine in ml/min.
Measure: Mean change in Serum Creatinine clearance. Time: up to 4 weeks.Description: Recording the changes in Glomerular filtration rate (GFR ) ml/min/m2.
Measure: Mean change in Glomerular filtration rate (GFR ). Time: up to 4 weeks.Description: Recording the changes in interleukin-1 (IL-1) in pg/ml.
Measure: The mean change in serum interleukin-1 (IL-1). Time: up to 4 weeks.Description: Recording the changes in interleukin-6 (IL-6) in pg/ml.
Measure: The mean change in serum interleukin-6 (IL-6). Time: up to 4 weeks.Description: Recording the changes in interleukin-10 (IL-10) in pg/ml.
Measure: The mean change in serum interleukin-10 (IL-10). Time: up to 4 weeks.Description: Recording the changes in tumor necrosis factor-alpha (TNF alpha) in ng/ml.
Measure: The mean change in serum tumor necrosis factor-alpha (TNF alpha). Time: up to 4 weeks.Description: Recording the changes in immunoglobulin G (IgG) in ng/ml.
Measure: Mean changes in immunoglobulin G (IgG). Time: up to 4 weeks.Description: Recording the changes in immunoglobulin M (IgM) in ng/ml.
Measure: Mean changes in immunoglobulin M (IgM). Time: up to 4 weeks.Description: Recording the changes in PCR viral load in copies/mL.
Measure: The mean change in PCR viral load. Time: up to 4 weeks.Description: Recording the changes in lung CT.
Measure: Mean change in lung CT manifestation. Time: up to 4 weeks.Description: Recording any unexpected Adverse Events of the intervention.
Measure: Nature and severity of Adverse Events. Time: up to 4 weeks.Description: Recording the changes (the average time of lung imaging recovery), as assessed by lung CT.
Measure: Time for lung recovery. Time: up to 8 weeks.Description: Recording the changes the event of missed drug doses.
Measure: The number of missed drug doses among each treatment group. Time: up to 4 weeks.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports